News releases Year None 2026 2025 2024 2023 2022 2021 2019 Sep 09, 2026 Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board PDF Version Sep 01, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Aug 13, 2026 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version Jun 30, 2026 Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones PDF Version May 14, 2026 Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version May 13, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version May 07, 2026 Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer PDF Version Apr 17, 2026 Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
Year None 2026 2025 2024 2023 2022 2021 2019 Sep 09, 2026 Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board PDF Version Sep 01, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Aug 13, 2026 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version Jun 30, 2026 Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones PDF Version May 14, 2026 Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version May 13, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version May 07, 2026 Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer PDF Version Apr 17, 2026 Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
